✦ LIBER ✦

Treatment of Patients With Acute Promyelocytic Leukemia: A Consensus Statement on Risk-Adapted Approaches to Therapy

✍ Scribed by Martin Tallman; Dan Douer; Steven Gore; Bayard L. Powell; Farhad Ravandi; Jacob Rowe; Aarati Ranganathan; Miguel A. Sanz

Book ID: 119936312
Publisher: Elsevier
Year: 2010
Tongue: English
Weight: 116 KB
Volume: 10
Category: Article
ISSN: 2152-2650
DOI: 10.3816/clml.2010.s.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of Newly Diagnosed Multiple My

Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement

✍ Dispenzieri, Angela; Rajkumar, S. Vincent; Gertz, Morie A.; Lacy, Martha Q.; Kyl 📂 Article 📅 2007 🏛 Mayo Clinic 🌐 English ⚖ 142 KB

Influence of time to complete remission

Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols

✍ Breccia, Massimo; Minotti, Clara; Latagliata, Roberto; Loglisci, Giuseppina; Sal 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 145 KB

An efficient therapeutic approach to pat

An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid

✍ Guanjun Wang; Wei Li; Jiuwei Cui; Sujun Gao; Cheng Yao; Zhenyu Jiang; Yanqiu Son 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract The use of arsenic trioxide (As~2~O~3~, ATO) combined with all‐trans retinoic acid (ATRA) has recently been reported to induce remission in patients with acute promyelocytic leukemia (APL). However, its efficiency remains inconclusive mainly due to the small number of the available case

A scoring system to predict the risk of

A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia

✍ David Valcárcel; Pau Montesinos; Isabel Sánchez-Ortega; Salut Brunet; Jordi Este 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB 👁 2 views

## Abstract ## BACKGROUND: A prognostic index to predict induction death in adult patients receiving induction chemotherapy for de novo acute myeloid leukemia (AML) was developed. ## METHODS: The authors analyzed 570 patients (aged 16‐70 years) included in 2 multicenter trials of the CETLAM Grou

Adding arabinosylcytosine to idarubicin

Adding arabinosylcytosine to idarubicin induction therapy may not improve survival for people with newly diagnosed acute promyelocytic leukaemia: Abstracted from: Avvisati G, Petti M, Lo-Coco F et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study. LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100 (9): 3141–6.

✍ Elihu Estey; Miguel A. Sanz 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 77 KB